Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | F2 | P00734 | 3/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31605318 | 1.00 | CA1 (0.63) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL57524 | 1.00 | CA1 (0.63) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL1584839 | 0.98 | CA1 (0.61) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL1584838 | 0.98 | CA1 (0.61) | CA1CA2CA9F2PRSS1 | |
| Dimethylamine SCHEMBL28365350 | 0.92 | CA1 (0.55) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL11485250 | 0.90 | HPRT1 (0.56) | CA1CA2CA9F2PRSS1 | |
| Acetamide SCHEMBL11095227 | 0.87 | CA1 (0.55) | CA1CA2CA9F2PRSS1 | |
| Pyridine SCHEMBL6537017 | 0.87 | CA2 (0.50) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL3576602 | 0.86 | CA1 (0.49) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL7729945 | 0.86 | CA1 (0.53) | CA1CA2CA9F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301859-A1 | ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Code Biotherapeutics, Inc. (US) | 2024-01-10 | — | — | EP | claimed |
| WO-2022187586-A1 | ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | CODE BIOTHERAPEUTICS, INC. (US) | 2022-09-09 | — | — | WO | claimed |
| WO-2026100443-A1 | RESIN, COMPOSITION, PHOTOCROSSLINKED PRODUCT, AND ELECTRONIC DEVICE COMPRISING SAME | 東ソー株式会社 | 2026-05-15 | — | — | WO | disclosed |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| WO-2025229046-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | MOLIUS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2025-11-06 | — | — | WO | disclosed |
| EP-4634226-A1 | ANTIBODIES TO CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) AND USES THEREOF | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| EP-4612186-A2 | MONOCLONAL ANTIBODIES SPECIFIC FOR FAS LIGAND AND USES THEREOF | Providence Health & Services - Oregon (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | disclosed |
| CN-120065625-A | Photoresist composition and preparation method and application thereof | 中国科学院光电技术研究所 | 2025-05-30 | — | — | CN | disclosed |
| EP-4558479-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024216167-A1 | COMPOSITIONS COMPRISING MODULATORS OF RIBONUCLEOPROTEIN GRANULE FORMATION AND DISSOLUTION AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2022184853-A1 | ANTI-VSIG4 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2022-09-09 | — | — | WO | disclosed |
| EP-4048285-A1 | TIM-3 INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| WO-2022165127-A2 | TREATMENT OF INTEGRIN-RELATED DISORDERS WITH STAPLED PEPTIDES | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-4025606-A1 | ANTI-VSIG4 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND USES THEREOF | Y-Biologics Inc. (KR) | 2022-07-13 | — | — | EP | disclosed |
| WO-2022136838-A1 | PLANT GROWTH PROMOTERS | UNIVERSITY OF DURHAM (GB) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022139681-A1 | METHODS FOR IDENTIFYING AND MONITORING INTERACTIONS OF PROTEIN WITH LIGAND | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022120048-A1 | HDAC INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-06-09 | — | — | WO | disclosed |
| CN-114173880-A | Methods of predicting cancer responsiveness to iron death induction therapy | 纪念斯隆凯特琳癌症中心 | 2022-03-11 | — | — | CN | disclosed |
| EP-3959233-A1 | NETRIN G1 AND NETRIN G1 LIGAND PEPTIDES AND ANTIBODIES AND USES THEREOF | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | CA1 740/4885CA2 1669/4885CA9 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.